Core Viewpoint - Via Biotech (01873) shares rose over 13% following the announcement of a significant acquisition deal between Swedish Orphan Biovitrum AB (Sobi) and Arthrosi, in which Via Biotech is involved [1] Group 1: Acquisition Details - Sobi announced an acquisition agreement with Arthrosi, with a total transaction value of up to $1.5 billion, which includes an upfront payment of $950 million and up to $550 million in regulatory and commercial milestone payments [1] - The transaction is expected to be completed in the first half of 2026 [1] Group 2: Financial Implications for Via Biotech - Via Biotech anticipates receiving up to approximately $40 million in investment returns from this transaction, contingent on subsequent regulatory approvals and the achievement of commercialization milestones [1] - Arthrosi has established a new Statement of Work (SOW) with Via Biotech's CDMO subsidiary, Langhua Pharmaceutical, for the supply of active pharmaceutical ingredients, indicating ongoing business collaboration [1]
港股异动 | 维亚生物(01873)涨超13% 投资孵化公司Arthrosi与Sobi达成收购